SYNOX Trademark

Trademark Overview


On Tuesday, June 1, 2021, a trademark application was filed for SYNOX with the United States Patent and Trademark Office. The USPTO has given the SYNOX trademark a serial number of 90747052. The federal status of this trademark filing is REGISTERED as of Tuesday, December 27, 2022. This trademark is owned by SynOx Therapeutics Limited. The SYNOX trademark is filed in the Pharmaceutical Products category with the following description:

Humanised antibody-based drugs for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases; pharmaceutical products, namely, humanised antibody emactuzumab targeting the CSF1R (colony stimulating factor 1 receptor) in cancer for the treatment of cancer and inflammatory diseases; pharmaceutical products, namely, inhibitors of CSF1R and macrophage function for the treatment of cancer and/or other oncological, autoimmune and inflammatory diseases; pharmaceutical products, namely, inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of TGCT (tenosynovial giant cell tumour)/PVNS (pigmented villonodular synovitis); pharmaceutical compounds for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer and/or other...
synox

General Information


Serial Number90747052
Word MarkSYNOX
Filing DateTuesday, June 1, 2021
Status700 - REGISTERED
Status DateTuesday, December 27, 2022
Registration Number6933250
Registration DateTuesday, December 27, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 11, 2022

Trademark Statements


Goods and ServicesHumanised antibody-based drugs for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases; pharmaceutical products, namely, humanised antibody emactuzumab targeting the CSF1R (colony stimulating factor 1 receptor) in cancer for the treatment of cancer and inflammatory diseases; pharmaceutical products, namely, inhibitors of CSF1R and macrophage function for the treatment of cancer and/or other oncological, autoimmune and inflammatory diseases; pharmaceutical products, namely, inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of TGCT (tenosynovial giant cell tumour)/PVNS (pigmented villonodular synovitis); pharmaceutical compounds for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases; biological preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 25, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSynOx Therapeutics Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDublin D02KC57
IE

Party NameSynOx Therapeutics Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDublin D02KC57
IE

Party NameSynOx Therapeutics Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDublin D02KC57
IE

Trademark Events


Event DateEvent Description
Tuesday, December 27, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, December 27, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, October 11, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 11, 2022PUBLISHED FOR OPPOSITION
Wednesday, September 21, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 6, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 12, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, August 12, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, August 12, 2022ASSIGNED TO LIE
Tuesday, July 19, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 22, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 22, 2022NON-FINAL ACTION E-MAILED
Tuesday, February 22, 2022NON-FINAL ACTION WRITTEN
Tuesday, February 15, 2022ASSIGNED TO EXAMINER
Wednesday, August 25, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, June 4, 2021NEW APPLICATION ENTERED IN TRAM